drug delivery

News

BMS' subcutaneous Opdivo clears first phase 3 trial

Bristol-Myers Squibb is getting closer to offering a subcutaneous version of its cancer immunotherapy Opdivo to patients after it matched the current intravenous formulati

News

Roche bags EU okay for subcutaneous Tecentriq

Roche has been given EU approval for a new formulation of its cancer immunotherapy Tecentriq that aims to make dosing easier for patients, nurses, and physicians.

R&D

Is the future of pharmaceutical drugs in the delivery?

Pharmaceutical drugs have seen a seismic shift over the past ten years, moving away from chemically synthesised drugs to focus more on a new class of biological drugs (biologics).<

News

FDA panel votes against Intarcia’s GLP-1 implant

Intarcia Therapeutics’ take on the massively successful GLP-1 agonist class of diabetes drugs has failed to convince an FDA advisory committee, which voted unanimously aga

News

GB first to approve Roche's subcutaneous Tecentriq

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has become the first regulator to approve Roche's subcutaneous (SC) formulation of cancer immunotherapy

News

Chiesi partners Aliada on brain-penetrating CNS therapies

Rare disease specialist Chiesi Pharma has forged an alliance with US biotech Aliada Therapeutics that will apply a technology designed to get drug molecules across the blo

BMS' subcutaneous Opdivo clears first phase 3 trial

Roche bags EU okay for subcutaneous Tecentriq

Is the future of pharmaceutical drugs in the delivery?

FDA panel votes against Intarcia’s GLP-1 implant

GB first to approve Roche's subcutaneous Tecentriq

Chiesi partners Aliada on brain-penetrating CNS therapies

Agios mulls early FDA filing for sickle cell therapy

Using AI-driven synthetic personas to take your insights fur...

drug delivery

Editor's Picks